Insight

Tony Cillo: Excited to share our paper on anti-PD1+anti-LAG3 therapy in melanoma

Photo take from Tony Cillo/X

Aug 9, 2024, 12:57

Tony Cillo: Excited to share our paper on anti-PD1+anti-LAG3 therapy in melanoma

Tony Cillo, Assistant professor in the Department of Immunology at the University of Pittsburgh.

“Excited to share our paper out today in Cell with Tullia Bruno from Vignali Lab! Part of a trio of papers, we show in Melanoma, anti-PD1+anti-LAG3 therapy modifies CD8 differentiation to promote enhanced effector function.

‘Blockade of LAG-3 and PD-1 leads to co-expression of cytotoxic and exhaustion gene modules in CD8⁺ T cells to promote antitumor immunity‘

Authors: Anthony R. Cillo, Carly Cardello, Feng Shan, Lilit Karapetyan, Sheryl Kunning, Cindy Sander, Elizabeth Rush, Arivarasan Karunamurthy, Ryan C. Massa, Anjali Rohatgi, Creg J. Workman, John M. Kirkwood, Tullia C. Bruno, Dario A.A. Vignali.”

Source: Tony Cillo/X

Anjali Rohatgi Anthony R. Cillo Arivarasan Karunamurthy cancer Carly Cardello Cindy Sander Creg J. Workman Dario A.A. Vignali Elizabeth Rush Feng Shan John M. Kirkwood Lilit Karapetyan Melanoma OncoDaily Oncology Ryan C. Massa Sheryl Kunning Tony Cillo Tullia Bruno Tullia C. Bruno Vignali Lab

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Agenus and Tanner Pharma Partner to Expand Global Access to BOT/BAL

Bispecific Antibody M701 Offers a Novel Treatment Option for Malignant Ascites

Special Coverage